Reports
Sale
Dysmenorrhea Market Size, Share, Trends, Analysis, Forecast: By Treatment Type: Non-steroidal Anti-inflammatory Drugs (NSAIDs), Hormonal Therapy; By Disease Type: Primary Dysmenorrhea, Secondary Dysmenorrhea; By End User: Hospitals, Homecare, Specialty Clinics, Others; Regional Analysis; Market Dynamics; Supplier Landscape; 2024-2032
Dysmenorrhea Market Outlook
The dysmenorrhea market size is expected to grow at a CAGR of 5.7% during the forecast period of 2024-2032, driven by the rising incidence of endometriosis and uterine fibroids due to hormonal imbalances in women across major markets.
Dysmenorrhea Market Overview
Dysmenorrhea, also known as menstrual cramps, is a condition characterized by extreme pains in the lower abdomen. The pain may start 2-3 days prior to the onset of menstruation. The condition can be broadly categorized into primary and secondary dysmenorrhea. Secondary dysmenorrhea may be caused by other medical conditions like endometriosis, pelvic inflammatory disease, or uterine fibroids. Around 3.8% of young women with reproductive tract anomalies along with obstructive and non-obstructive anomalies may be related to secondary dysmenorrhea.
The rising dysmenorrhea market demand is directly impacted by the rising prevalence of conditions such as PCOS, adenomyosis, endometriosis or uterine fibroids. Dysmenorrhea affects approximately 16% to 91% of the population in their reproductive age, with a high prevalence in adolescents (around 80%). Around 40% of adolescents are affected by severe dysmenorrhea. Severe pain is observed in 2-29% of individuals, and it impairs the quality of life of around 16-29% of the women. In addition, 12% of work and school activities may be affected due to absenteeism caused by dysmenorrhea.
Innovation in Existing Treatment Methods in the Dysmenorrhea Market
In December 2023, Dare Bioscience revealed a non-pharmacologic pain relief method for treating dysmenorrhea pain. DARE-PDM1 is a 1% diclofenac vaginal hydrogel being investigated to treat pain and was well-tolerated in the clinical assessment of 42 premenopausal women across various centers. This is the first-in-category product delivering diclofenac in a vaginal format which is expected to extend the duration of pain relief and reduce the risk of side effects associated with oral delivery of NSAIDs. The advent of the latest methods is projected to boost the dysmenorrhea market share in the forecast period as well.
Focus on Alternative Methods to Address a Wider Section of Patients
In November 2023, an Ayurvedic cannabis startup called HempStreet raised USD 1 million in pre-Series A funding aimed at expanding its activities delivering effective menstrual cramps and pain treatment segment by facilitating expediated research and development and clinical trials for developing ayurveda-inspired products. Such initiatives are expected to bolster the dysmenorrhea market growth across the world.
Development in Surgical Procedures to Offer Alternatives to Pharmacological Interventions
Along with pharmacological interventions, surgical procedures are also used for patients with persistent and prolonged menstrual pain. Transcutaneous electrical nerve stimulation, empiric GnRH analog therapy is generally used as a second-tier treatment intervention with nonhormonal and/or hormonal therapies.
The rising advances in medical and healthcare technologies further fuel the dysmenorrhea market value. In severe cases, endometrial ablation and hysterectomy are also used. In July 2023, a new hysterectomy procedure called Vaginal Natural Orifice Transluminal Endoscopic Surgery (vNOTES ), that leaves no scars and causes minimal pain was performed at an Australian hospital for the first time. It offers a better approach to the fallopian tubes and ovaries and helps with reduced recovery time when compared to standard procedures.
In addition, other supportive therapies such as behavioral counselling, physiotherapy treatments and alternative medicines such as acupressure along with proper nutrition are also prescribed by healthcare professionals. This indicates the rising adoption naturopathy to treat dysmenorrhea.
Adoption of Combination Treatment is a Vital Dysmenorrhea Market Trend
The first-tier treatment for dysmenorrhea includes medications such as nonsteroidal anti-inflammatory drugs (NSAIDs), acetaminophen (paracetamol), and hormonal contraception. However, to offer improved treatment solutions to patients, combination therapies are employed in patients. Estrogen-progestin pills such as oral pills, transdermal patches and vaginal rings are some of the commonly used treatment alternatives. Progestin only options are also available which constitute injections and levonorgestrel (LNG) releasing intrauterine devices among others. In a July 2023 study conducted by Cochrane researchers, revealed that combined oral contraceptive pills may be the upcoming treatment alternative as it has displayed promising results in treating dysmenorrhea well.
Dysmenorrhea Market Segmentation
Market Breakup by Treatment Type
- Non-steroidal Anti-inflammatory Drugs (NSAIDs)
- Hormonal Therapy
Market Breakup by Disease Type
- Primary Dysmenorrhea
- Secondary Dysmenorrhea
Market Breakup by End User
- Hospitals
- Homecare
- Specialty Clinics
- Others
Market Breakup by Region
- United States
- EU-4 and the United Kingdom
- Germany
- France
- Italy
- Spain
- United Kingdom
- Japan
Dysmenorrhea Market Regional Analysis
North America, particularly United States and Canada, is anticipated to lead the dysmenorrhea market share in the forecast period. The high prevalence of the condition in the region is a major aspect of the market size as women leading a sedentary lifestyle and following unhealthy dietary habits are more susceptible to develop the condition. In addition, the well-structured medical ecosystem facilitates easy availability of over the counter (OTC) pain relief medications, which further fuels the market share.
In Europe, there is a typically higher awareness of women’s health issues along with a well-developed healthcare infrastructure. Hence, it is a major player in the market. The market is currently witnessing a mix of both pharmaceutical as well as naturopathy therapies, as the population is inclining towards holistic homecare remedies for treating dysmenorrhea. Such cultural shifts will impact on the market value significantly in the forecast period.
The Asia Pacific dysmenorrhea market growth is driven by the increasing prevalence of traditional medicine and herbal remedies to treat the condition. With a substantial part of the population suffering from dysmenorrhea, several non-profit organizations and prominent healthcare companies are setting up essential awareness campaigns to educate the rural community about the disease. Alternatively, there have been significant efforts to improve the healthcare infrastructure as well.
Dysmenorrhea Market: Competitor Landscape
In October 2023, Mithra Biotech , a company dedicated to women’s health received approximately USD 3 million investment from Fuji Pharma. With the investment, Mithra envisions at redefining fem health by delivering innovative products in the domain of menopause as well as contraception. This also indicates the rising trend of growth in fundings to expand product portfolios.
The key features of the dysmenorrhea market report include patent analysis, grants analysis, clinical trials analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the market are as follows:
- Novartis AG
- Bayer AG
- Abbott Laboratories
- F. Hoffmann-La Roche Ltd
- Sanofi
- Pfizer Inc.
- GlaxoSmithKline PLC
- Focus Consumer Healthcare
- Johnson & Johnson
- Alvogen
- Amgen Inc.
- Boehringer Ingelheim International GmbH.
- Ipsen Pharm
- Spectrum Pharmaceuticals, Inc.
- Takeda Pharmaceutical Company Limited
Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.
Key Highlights of the Report
| REPORT FEATURES | DETAILS |
| Base Year | 2023 |
| Historical Period | 2017-2023 |
| Forecast Period | 2024-2032 |
| Scope of the Report |
Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:
|
| Breakup by Treatment Type |
|
| Breakup by Disease Type |
|
| Breakup by End User |
|
| Breakup by Region |
|
| Market Dynamics |
|
| Competitive Landscape |
|
| Companies Covered |
|
*At Expert Market Research, we strive to always give you current and accurate information. The numbers depicted in the description are indicative and may differ from the actual numbers in the final EMR report.
1 Preface
1.1 Objectives of the Study
1.2 Key Assumptions
1.3 Report Coverage – Key Segmentation and Scope
1.4 Research Methodology
2 Executive Summary
3 Dysmenorrhea Overview
3.1 Guidelines and Stages
3.2 Pathophysiology
3.3 Screening and Diagnosis
3.4 Treatment Pathway
4 Patient Profile
4.1 Patient Profile Overview
4.2 Patient Psychology and Emotional Impact Factors
4.3 Risk Assessment and Treatment Success Rate
5 Dysmenorrhea Epidemiology Analysis – 7MM
5.1 7MM Epidemiology Scenario Overview (2017-2032)
5.2 United States Dysmenorrhea Epidemiology Forecast (2017-2032)
5.3 EU-4 and United Kingdom Dysmenorrhea Epidemiology Forecast (2017-2032)
5.3.1 Germany Dysmenorrhea Epidemiology Forecast (2017-2032)
5.3.2 France Dysmenorrhea Epidemiology Forecast (2017-2032)
5.3.3 Italy Dysmenorrhea Epidemiology Forecast (2017-2032)
5.3.4 Spain Dysmenorrhea Epidemiology Forecast (2017-2032)
5.3.5 United Kingdom Dysmenorrhea Epidemiology Forecast (2017-2032)
5.4 Japan Dysmenorrhea Epidemiology Forecast (2017-2032)
6 Dysmenorrhea Market Overview – 7MM
6.1 Dysmenorrhea Market Historical Value (2017-2023)
6.2 Dysmenorrhea Market Forecast Value (2024-2032)
7 Dysmenorrhea Market Landscape – 7MM
7.1 Dysmenorrhea: Developers Landscape
7.1.1 Analysis by Year of Establishment
7.1.2 Analysis by Company Size
7.1.3 Analysis by Region
7.2 Dysmenorrhea Product Landscape
7.2.1 Analysis by Treatment Type
7.2.2 Analysis by Route of Administration
7.2.3 Analysis by Treatment Type
8 Dysmenorrhea Challenges and Unmet Needs
8.1 Treatment Pathway Challenges
8.2 Compliance and Drop-Out Analysis
8.3 Awareness and Prevention Gaps
9 Cost of Treatment
10 Dysmenorrhea Market Dynamics
10.1 Market Drivers and Constraints
10.2 SWOT Analysis
10.3 Porter’s Five Forces Model
10.4 Key Demand Indicators
10.5 Key Price Indicators
10.6 Industry Events, Initiatives, and Trends
10.7 Value Chain Analysis
11 Dysmenorrhea Market Segmentation – 7MM
11.1 Dysmenorrhea Market by Treatment Type
11.1.1 Market Overview
11.1.2 Non-steroidal Anti-inflammatory Drugs (NSAIDs)
11.1.3 Hormonal Therapy
11.2 Dysmenorrhea Market by Disease Type
11.2.1 Market Overview
11.2.2 Primary Dysmenorrhea
11.2.3 Secondary Dysmenorrhea
11.3 Dysmenorrhea Market by End User
11.3.1 Market Overview
11.3.2 Hospitals
11.3.3 Homecare
11.3.4 Specialty Clinics
11.3.5 Others
11.4 Dysmenorrhea Market by Region
11.4.1 Market Overview
11.4.2 United States
11.4.3 EU-4 and the United Kingdom
11.4.3.1 Germany
11.4.3.2 France
11.4.3.3 Italy
11.4.3.4 Spain
11.4.3.5 United Kingdom
11.4.4 Japan
12 United States Dysmenorrhea Market
12.1 Dysmenorrhea Market Historical Value (2017-2023)
12.2 Dysmenorrhea Market Forecast Value (2024-2032)
12.3 Dysmenorrhea Market by Disease Type
12.4 Dysmenorrhea Market by Treatment Type
13 EU-4 and United Kingdom Dysmenorrhea Market
13.1 Dysmenorrhea Market Historical Value (2017-2023)
13.2 Dysmenorrhea Market Forecast Value (2024-2032)
13.3 Germany Dysmenorrhea Market Overview
13.3.1 Dysmenorrhea Market by Disease Type
13.3.2 Dysmenorrhea Market by Treatment Type
13.4 France Dysmenorrhea Market Overview
13.4.1 Dysmenorrhea Market by Disease Type
13.4.2 Dysmenorrhea Market by Treatment Type
13.5 Italy Dysmenorrhea Market Overview
13.5.1 Dysmenorrhea Market by Disease Type
13.5.2 Dysmenorrhea Market by Treatment Type
13.6 Spain Dysmenorrhea Market Overview
13.6.1 Dysmenorrhea Market by Disease Type
13.6.2 Dysmenorrhea Market by Treatment Type
13.7 United Kingdom Dysmenorrhea Market Overview
13.7.1 Dysmenorrhea Market by Disease Type
13.7.2 Dysmenorrhea Market by Treatment Type
14 Japan Dysmenorrhea Market
14.1 Dysmenorrhea Market Historical Value (2017-2023)
14.2 Dysmenorrhea Market Forecast Value (2024-2032)
14.3 Dysmenorrhea Market by Disease Type
14.4 Dysmenorrhea Market by Treatment Type
15 Regulatory Framework
15.1 Regulatory Overview
15.1.1 US FDA
15.1.2 EU EMA
15.1.3 JAPAN PMDA
16 Patent Analysis
16.1 Analysis by Type of Patent
16.2 Analysis by Publication year
16.3 Analysis by Issuing Authority
16.4 Analysis by Patent Age
16.5 Analysis by CPC Analysis
16.6 Analysis by Patent Valuation
16.7 Analysis by Key Players
17 Grants Analysis
17.1 Analysis by year
17.2 Analysis by Amount Awarded
17.3 Analysis by Issuing Authority
17.4 Analysis by Grant Application
17.5 Analysis by Funding Institute
17.6 Analysis by NIH Departments
17.7 Analysis by Recipient Organization
18 Clinical Trials Analysis
18.1 Analysis by Trial Registration Year
18.2 Analysis by Trial Status
18.3 Analysis by Trial Phase
18.4 Analysis by Therapeutic Area
18.5 Analysis by Geography
19 Funding and Investment Analysis
19.1 Analysis by Funding Instances
19.2 Analysis by Type of Funding
19.3 Analysis by Funding Amount
19.4 Analysis by Leading Players
19.5 Analysis by Leading Investors
19.6 Analysis by Geography
20 Partnerships and Collaborations Analysis
20.1 Analysis by Partnership Instances
20.2 Analysis by Type of Partnership
20.3 Analysis by Leading Players
20.4 Analysis by Geography
21 Supplier Landscape
21.1 Novartis AG
21.1.1 Financial Analysis
21.1.2 Product Portfolio
21.1.3 Demographic Reach and Achievements
21.1.4 Mergers and Acquisitions
21.1.5 Certifications
21.2 Bayer AG
21.2.1 Financial Analysis
21.2.2 Product Portfolio
21.2.3 Demographic Reach and Achievements
21.2.4 Mergers and Acquisitions
21.2.5 Certifications
21.3 Abbott Laboratories
21.3.1 Financial Analysis
21.3.2 Product Portfolio
21.3.3 Demographic Reach and Achievements
21.3.4 Mergers and Acquisitions
21.3.5 Certifications
21.4 F. Hoffmann-La Roche Ltd
21.4.1 Financial Analysis
21.4.2 Product Portfolio
21.4.3 Demographic Reach and Achievements
21.4.4 Mergers and Acquisitions
21.4.5 Certifications
21.5 Sanofi
21.5.1 Financial Analysis
21.5.2 Product Portfolio
21.5.3 Demographic Reach and Achievements
21.5.4 Mergers and Acquisitions
21.5.5 Certifications
21.6 Pfizer Inc.
21.6.1 Financial Analysis
21.6.2 Product Portfolio
21.6.3 Demographic Reach and Achievements
21.6.4 Mergers and Acquisitions
21.6.5 Certifications
21.7 GlaxoSmithKline PLC
21.7.1 Financial Analysis
21.7.2 Product Portfolio
21.7.3 Demographic Reach and Achievements
21.7.4 Mergers and Acquisitions
21.7.5 Certifications
21.8 Focus Consumer Healthcare
21.8.1 Financial Analysis
21.8.2 Product Portfolio
21.8.3 Demographic Reach and Achievements
21.8.4 Mergers and Acquisitions
21.8.5 Certifications
21.9 Johnson & Johnson
21.9.1 Financial Analysis
21.9.2 Product Portfolio
21.9.3 Demographic Reach and Achievements
21.9.4 Mergers and Acquisitions
21.9.5 Certifications
21.10 Alvogen
21.10.1 Financial Analysis
21.10.2 Product Portfolio
21.10.3 Demographic Reach and Achievements
21.10.4 Mergers and Acquisitions
21.10.5 Certifications
21.11 Amgen Inc.
21.11.1 Financial Analysis
21.11.2 Product Portfolio
21.11.3 Demographic Reach and Achievements
21.11.4 Mergers and Acquisitions
21.11.5 Certifications
21.12 Boehringer Ingelheim International GmbH.
21.12.1 Financial Analysis
21.12.2 Product Portfolio
21.12.3 Demographic Reach and Achievements
21.12.4 Mergers and Acquisitions
21.12.5 Certifications
21.13 Ipsen Pharm
21.13.1 Financial Analysis
21.13.2 Product Portfolio
21.13.3 Demographic Reach and Achievements
21.13.4 Mergers and Acquisitions
21.13.5 Certifications
21.14 Spectrum Pharmaceuticals, Inc.
21.14.1 Financial Analysis
21.14.2 Product Portfolio
21.14.3 Demographic Reach and Achievements
21.14.4 Mergers and Acquisitions
21.14.5 Certifications
21.15 Takeda Pharmaceutical Company Limited
21.15.1 Financial Analysis
21.15.2 Product Portfolio
21.15.3 Demographic Reach and Achievements
21.15.4 Mergers and Acquisitions
21.15.5 Certifications
22 Dysmenorrhea Market- Distribution Model (Additional Insight)
22.1 Overview
22.2 Potential Distributors
22.3 Key Parameters for Distribution Partner Assessment
23 Key Opinion Leaders (KOL) Insights (Additional Insight)
24 Company Competitiveness Analysis (Additional Insight)
24.1 Very Small Companies
24.2 Small Companies
24.3 Mid-Sized Companies
24.4 Large Companies
24.5 Very Large Companies
25 Payment Methods (Additional Insight)
25.1 Government Funded
25.2 Private Insurance
25.3 Out-of-Pocket
*Additional insights provided are customisable as per client requirements.
Key Questions Answered in the Report
The market is anticipated to grow at a CAGR of 5.7% during the forecast period of 2024-2032, driven by the growing incidence of uterine fibroids, endometriosis and adenomyosis.
The market demand is driven by increased interest in improving women’s reproductive health with natural remedies and technological innovations in healthcare.
The major market trend revolves around the rising application of combination treatment methods to treat dysmenorrhea. Oral contraceptive pills are being tested as a potential intervention and have demonstrated positive results in management. There is growing investigations in developing better surgical management methods as well.
Based on treatment types, the market is divided into non-steroidal anti-inflammatory drugs (NSAIDs) and hormonal therapy.
Who are the major end users in the market?
Major end users include hospitals, homecare, and speciality clinics.
It includes primary and secondary dysmenorrhea.
The major regions of the market include the United States, Japan, EU-4 which is segmented into Germany, France, Italy, Spain, and the United Kingdom.
Key players involved in the market are Novartis AG, Bayer AG, Abbott Laboratories, F. Hoffmann-La Roche Ltd., Sanofi, Pfizer Inc., GlaxoSmithKline PLC, Focus Consumer Healthcare, Johnson & Johnson, Alvogen, Amgen Inc., Boehringer Ingelheim International GmbH., Ipsen Pharm, Spectrum Pharmaceuticals, Inc., and Takeda Pharmaceutical Company Limited.
Purchase Options 10% off
Call us
Purchase Full Report
Mini Report
$ 3299
$2999
-
Selected Sections, One User
-
Printing Not Allowed
-
Email Delivery in PDF
-
Free Limited Customisation -
Post Sales Analyst Support -
50% Discount on Next Update
Single User License
$ 6599
$5999
-
All Sections, One User
-
One Print Allowed
-
Email Delivery in PDF
-
Free Limited Customisation -
Post Sales Analyst Support -
50% Discount on Next Update
Five User License
$ 8799
$7999
-
All Sections, Five Users
-
Five Prints Allowed
-
Email Delivery in PDF
-
Free Limited Customisation
-
Post Sales Analyst Support
-
50% Discount on Next Update
Corporate License
$ 9899
$8999
-
All Sections, Unlimited Users
-
Unlimited Prints Allowed
-
Email Delivery in PDF + Excel
-
Free Limited Customisation
-
Post Sales Analyst Support
-
50% Discount on Next Update
Any Question? Speak With An Analyst
View A Sample
Did You Miss Anything, Ask Now
Why Expert Market Research?
Right People
We are technically excellent, strategic, practical, experienced and efficient; our analysts are hand-picked based on having the right attributes to work successfully and execute projects based on your expectations.
Right Methodology
We leverage our cutting-edge technology, our access to trusted databases, and our knowledge of the current models used in the market to deliver you research solutions that are tailored to your needs and put you ahead of the curve.
Right Price
We deliver in-depth and superior quality research in prices that are reasonable, unmatchable, and shows our understanding of your resource structure. We, additionally, offer attractive discounts on our upcoming reports.
Right Support
Our team of expert analysts are at your beck and call to deliver you optimum results that are customised to meet your precise needs within the specified timeframe and help you form a better understanding of the industry.
NEWSLETTER